Author(s)

Lu Zhou, Gang Cheng^*

Department of Nuclear Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.

Objective: The purpose of this study was to investigate the effect of Hashimoto’s thyroiditis on efficacy of ¹³¹I ablation in intermediate- and high-risk of thyroid papillary carcinoma patients. The findings will help to develop a personalized treatment plan for patients with thyroid papillary carcinoma complicated with Hashimoto’s thyroiditis. Material and Methods: From January 2016 to December 2020, patients who were diagnosed with intermediate- and high-risk PTC with lymph node metastasis were analyzed retrospectively, excluding patients with incomplete clinical data, distant metastasis, positive TGAb, TSH < 30 mIU/L. The baseline data of sex, age, and biochemical information were collected before admission. All patients included had radioactive iodine (RAI) with 3.70 GBq. The treatment response of patients was evaluated 6 - 8 months after discharge. By means of univariate and multivariate analysis, including excellent response (ER) and non-excellent response (NER) groups of clinical data, we assessed the impact of ¹³¹I on patients outcome. Results: A total of 525 patients (166 males and 359 females) were included in the study, including 368 patients in ER group (70.1%) and 157 patients in NER group (29.9%). Eleven factors including combining Hashimoto’s thyroiditis, pre-ablative Tg levels, sex, tumor diameter, extraglandular invasion, multifocal, bilateral lesions, central lymph node metastasis, lateral lymph node metastasis, lymph node metastasis rate, thyroglobulin were statistically different between ER group and NER group with significance at P < 0.05. Further multivariate analysis showed that Hashimoto’s thyroiditis, Ps-Tg levels and lateral lymph node metastasis could be used as independent factors. And patients with HT had significantly superior outcomes compared with patients without HT. Conclusion: Hashimoto’s thyroiditis, Ps-Tg level and lateral lymph node metastasis are potential predictors for short-term efficacy of ¹³¹I treatment in intermediate- and high-risk thyroid papillary carcinoma. Hashimoto’s thyroiditis, high Ps-Tg level and increased number of lateral lymph node metastasis reduce the efficacy of ¹³¹I therapy in patients with intermediate and high risk thyroid papillary carcinoma.

Papillary Thyroid Carcinoma, Hashimoto’s Thyroiditis, ¹³¹I Therapy, Curative Effect

Zhou, L. and Cheng, G. (2023) Effect of Hashimoto’s Thyroiditis on Efficacy of ¹³¹I Ablation Therapy in Intermediate- and High-Risk of Thyroid Papillary Carcinoma. Journal of Biosciences and Medicines, 11, 103-113. doi: 10.4236/jbm.2023.114008.